| __timestamp | ACADIA Pharmaceuticals Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 612613000000 |
| Thursday, January 1, 2015 | 90804000 | 650773000000 |
| Friday, January 1, 2016 | 186456000 | 619061000000 |
| Sunday, January 1, 2017 | 255062000 | 628106000000 |
| Monday, January 1, 2018 | 265758000 | 717599000000 |
| Tuesday, January 1, 2019 | 325638000 | 964737000000 |
| Wednesday, January 1, 2020 | 388661000 | 875663000000 |
| Friday, January 1, 2021 | 396028000 | 886361000000 |
| Saturday, January 1, 2022 | 369090000 | 997309000000 |
| Sunday, January 1, 2023 | 402466000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, operational costs play a pivotal role in shaping company strategies. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: Takeda Pharmaceutical Company Limited and ACADIA Pharmaceuticals Inc., from 2014 to 2023.
Takeda, a global leader, consistently reported SG&A expenses exceeding $600 billion annually, peaking at over $1 trillion in 2023. This reflects a robust expansion strategy and significant market presence. In contrast, ACADIA, a smaller player, showed a steady increase in SG&A expenses, growing from $33 million in 2014 to $402 million in 2023, marking a growth of over 1,100%. This indicates ACADIA's aggressive investment in marketing and administrative capabilities to enhance its market footprint.
The data highlights the contrasting scales and strategies of these companies, offering insights into their operational priorities and market dynamics.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and MorphoSys AG
Who Optimizes SG&A Costs Better? ACADIA Pharmaceuticals Inc. or MannKind Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends